Key Developments: Auxilium Pharmaceuticals Inc (AUXL.O)

AUXL.O on Nasdaq

19.30USD
3:57pm EDT
Price Change (% chg)

$-0.15 (-0.77%)
Prev Close
$19.45
Open
$18.98
Day's High
$19.51
Day's Low
$18.98
Volume
573,629
Avg. Vol
1,695,348
52-wk High
$32.89
52-wk Low
$16.36

Search Stocks

Latest Key Developments (Source: Significant Developments)

Auxilium Pharmaceuticals to merge with canadian biotechnology company QLT
Thursday, 26 Jun 2014 07:00am EDT 

Auxilium Pharmaceuticals Inc and QLT Inc:Enters into a definitive agreement under which Auxilium plans to merge with QLT.Transaction is expected to drive shareholder value creation by accelerating Auxilium's ongoing transformation into a diversified North American specialty biopharmaceutical company.Under the terms of the agreement, a wholly-owned subsidiary of QLT will be merged with and into Auxilium.QLT will remain incorporated in British Columbia, Canada, and will be renamed "New Auxilium.".Combined organization will be led by Auxilium's current leadership team and will maintain Auxilium's current offices in Chesterbrook, Pennsylvania.  Full Article

Auxilium Pharmaceuticals Inc partners with Prasco, LLC
Wednesday, 11 Jun 2014 07:00am EDT 

Auxilium Pharmaceuticals Inc:Says that it has partnered with Prasco, LLC to introduce an Authorized Generic version of Testim.Prasco has product inventory available and has commenced shipping product.Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat adult males who have low or no testosterone.  Full Article

Auxilium Pharmaceuticals Inc reaffirms FY 2014 guidance - Conference Call
Tuesday, 3 Jun 2014 10:00am EDT 

Auxilium Pharmaceuticals Inc:Expects FY 2014 net revenues of between $380 million and $420 million.Anticipates FY 2014 net income loss to be breakeven or a $15 million loss.FY 2014 revenue of $399 million and net income $(9) million - Thomson Reuters I/B/E/S.  Full Article

Auxilium Pharmaceuticals Inc announces departure of Chief Financial Officer
Monday, 2 Jun 2014 04:30pm EDT 

Auxilium Pharmaceuticals Inc:James E. Fickenscher, Chief Financial Officer, is leaving company to pursue other interests.Fickenscher will continue in his current role through Aug. 15.  Full Article

Auxilium Pharmaceuticals, Inc reaffirms FY 2014 guidance - Conference Call
Monday, 19 May 2014 11:00am EDT 

Auxilium Pharmaceuticals, Inc:Expects FY 2014 revenues of between $380 million and $420 million and a net income-loss of a range between breakeven to $15 million in loss.FY 2014 revenue of $399 million and net income of $(5) million - Thomson Reuters I/B/E/S.  Full Article

Auxilium Pharmaceuticals Inc lowers FY 2014 guidance
Tuesday, 29 Apr 2014 07:05pm EDT 

Auxilium Pharmaceuticals Inc:Revises FY 2014 guidance.Sees FY 2014 total revenues between $380 - $420.Sees FY 2014 non-GAAP Net Income (Loss) of between $0 - $(15).  Full Article

Auxilium Pharmaceuticals Inc announces presentation of data for XIAFLEX at Urology meeting
Monday, 28 Apr 2014 07:00am EDT 

Auxilium Pharmaceuticals Inc:Announces presentations from multiple trials evaluating the use of XIAFLEX (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be presented at the upcoming American Urological Association (AUA) Meeting being held in Orlando, Florida on May 16-21.Podium presentations on XIAFLEX will include new analyses from the pivotal Phase 3 IMPRESS ( The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials.XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a penile curvature deformity of 30 degrees or greater at the start of therapy.  Full Article

Auxilium Pharmaceuticals Inc issues FY 2014 guidance; net income guidance below analysts' estimates
Friday, 28 Feb 2014 06:30am EST 

Auxilium Pharmaceuticals Inc:Expects FY 2014 global net revenues to be in the range of $450-$490 mln.FY 2014 net income on a non-GAAP basis to be in the range of $45-$50 mln.FY 2014 revenue of $489 mln and net income of $54 mln - Thomson Reuters I/B/E/S.  Full Article

Auxilium Pharmaceuticals Inc announces FDA acceptance of application requesting approval of XIAFLEX for concurrent treatment of multiple palpable cords
Monday, 24 Feb 2014 06:30am EST 

Auxilium Pharmaceuticals Inc:U.S. Food and Drug Administration (FDA) has accepted company's submission of supplemental Biologics License Application (sBLA).Says requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of two Dupuytren's contracture (DC) cords concurrently.Says PDUFA date for sBLA filing is Oct. 20.XIAFLEX is biologic approved in U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord.XIAFLEX in U.S. for treatment of adult men with Peyronie's disease (PD) with palpable plaque and curvature deformity of at least 30 degrees at start of therapy.  Full Article

Auxilium Pharmaceuticals Inc raises upper end of prior FY 2013 revenue guidance; gives FY 2013 net income guidance in line with analysts' estimates - Conference Call
Monday, 10 Feb 2014 09:00am EST 

Auxilium Pharmaceuticals Inc:Expects FY 2013 total revenues of between $370 million and $401 million.Expects FY 2013 non-GAAP net income in a range of $25 million to $30 million.FY 2013 revenue of $387 million and net income of $29 million - Thomson Reuters I/B/E/S.  Full Article

Deals of the day- Mergers and acquisitions

(Adds Martin Marietta Materials, Philips, TreeHouse Foods, Natixis, Banca Popolare di Vicenza; updates Gazprom, Petrofac, Auxilium, AMS, London Stock Exchange)

Search Stocks